Endogenous retrovirus group V member 2, envelope (ERVV-2)

Endogenous retrovirus group V member 2 (ERVV-2) is a human gene derived from an ancient retroviral infection that has been permanently integrated into the germline. It encodes an envelope polyprotein that is primarily expressed in the placenta, where it is thought to facilitate cell-cell fusion and syncytium formation, a role similar to other co-opted viral proteins like syncytins. In pathological contexts, ERVV-2 and other members of the ERV2 (Class II) superfamily can be reactivated through epigenetic dysregulation, leading to the production of viral transcripts and proteins that trigger 'viral mimicry' and chronic inflammatory responses. This aberrant expression is associated with various malignancies, including colorectal cancer and glioblastoma, as well as neurodegenerative conditions and responses to exogenous viral infections such as Influenza A and SARS-CoV-2. As a therapeutic target, ERVV-2 is being investigated for its potential in cancer immunotherapy and as a biomarker for disease progression, with current strategies focusing on the use of antiretroviral drugs and monoclonal antibodies to modulate its pathogenic activity.

Other names

HERV-V2ERVV2Endogenous retrovirus group V member 2 envelope polyproteinSyncytin-3ERV2

Inhibition of viral protein expression, neutralization of envelope-mediated inflammatory signaling, and inhibition of reverse transcription of reactivated retroviral elements.